Industry

Applied UV Installs Patented LumiCide Surface Disinfection Solution into NYC’s Mt. Sinai Medical Center Morningside

One of The World’s Prestigious Hospitals MOUNT VERNON, N.Y.–(BUSINESS WIRE)–Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its wholly owned … [Read more…]

Biting Down on Value: Overall Dental Plan Satisfaction Falls as Industry Consolidation Rises, J.D. Power Finds

Humana Dental Ranks Highest in Customer Satisfaction TROY, Mich.–(BUSINESS WIRE)–As dental practices continue to consolidate after two years of pandemic uncertainty, patient visits seem to be leaving a cavity of satisfaction. Overall satisfaction is down 15 points (on a 1,000-point scale) from a year ago, according to the J.D. Power 2022 U.S. Dental Plan Satisfaction … [Read more…]

TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets

Appoints Tuija Keinonen as Chair HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has completed the first close of its financing round raising $10.7 million (€10 million). The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance … [Read more…]

Digital Therapeutics Alliance and Healthware Group Partner to Build European Coalition to Scale Access to Digital Therapeutics

ARLINGTON, Va. & MILAN, Italy–(BUSINESS WIRE)–The Digital Therapeutics Alliance (DTA) and Healthware Group today announced a partnership to form a coalition convening thought leaders, policymakers, and professional and trade associations from across the European region to discuss and develop harmonised pathways for the recognition and scalability of digital therapeutics (DTx) at the local, national, and … [Read more…]

Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma

Study shows that DecisionDx®-Melanoma results can provide patients with knowledge and understanding regarding their prognosis and inform melanoma treatment decisions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a poster presentation on DecisionDx®-Melanoma at the recent 2022 Fall Clinical Dermatology Conference for … [Read more…]

World Innovation Lab Raises $1 Billion to Bridge the Innovation Gap Across the Global Venture Ecosystem

Influx of capital will fuel WiL Ventures III fund, WiL Strategic Partners funds and Corporate Venture Capital funds; WiL’s capital commitments now exceed $1.9 billion WiL’s mission: bridge the innovation gap between Japan, the US and the rest of the world WiL’s investment thesis: provide growth investment capital for innovators across the spectrum of digital … [Read more…]

Cardiawave Confirms the Safety of VALVOSOFT® its Non-Invasive Ultrasound Treatment for Aortic Stenosis

– No cerebral vascular anomaly before and after treatment observed – Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most … [Read more…]

General Anxiety Disorder Therapeutics Global Market Insights Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “General Anxiety Disorder Therapeutics Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type” report has been added to ResearchAndMarkets.com’s offering. This report describes the global market size of General Anxiety Disorder Therapeutics from 2017 to 2021 and its CAGR from 2017 to 2021, and also forecasts … [Read more…]

I-VASC announces the first clinical use of VELEX™, the Empty Vein Ablation (EVA) technology device to treat Chronic Venous Insufficiency (CVI).

MILAN–(BUSINESS WIRE)–#IVASC–I-VASC, the Italy based start-up company which has developed and CE Marked its innovative percutaneous VELEX™ system to treat CVI, a condition that includes varicose veins disease, announces today that VELEX™ has entered clinical use, with the first two cases performed last week in Milan at the Policlinico San Donato center, the renowned institution … [Read more…]

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab (Nasdaq: IMAB), recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, … [Read more…]